TY - JOUR T1 - Overweight/obesity as the potentially most important lifestyle factor associated with signs of pneumonia in COVID-19 JF - medRxiv DO - 10.1101/2020.07.23.20161042 SP - 2020.07.23.20161042 AU - Vanessa Sacco AU - Barbara Rauch AU - Christina Gar AU - Stefanie Haschka AU - Anne L. Potzel AU - Stefanie Kern-Matschilles AU - Friederike Banning AU - Irina Benz AU - Mandy Meisel AU - Jochen Seissler AU - Andreas Lechner Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/24/2020.07.23.20161042.abstract N2 - Objective The occurrence of pneumonia separates severe cases of COVID-19 from the majority of cases with mild disease. However, the factors determining whether or not pneumonia develops remain to be fully uncovered. We therefore explored the associations of several lifestyle factors with signs of pneumonia in COVID-19.Methods Between May and July 2020, we conducted an online survey of adults in Germany who had recently gone through COVID-19, predominantly as outpatients (n=201). Of these, 165 had a PCR-based diagnosis and 36 had a retrospective diagnosis by antibody testing. The survey covered demographic information, eight lifestyle factors, comorbidities and medication use. We defined the main outcome as the presence vs. the absence of signs of pneumonia, represented by dyspnea, the requirement for oxygen therapy or intubation.Results Signs of pneumonia occurred in 39 of the 165 individuals with a PCR-based diagnosis of COVID-19 (23.6%). Among the lifestyle factors examined, only overweight/obesity associated with signs of pneumonia (odds ratio 2.68 (1.29 - 5.59) p=0.008). The observed association remained significant after multivariate adjustment, with BMI as a metric variable, and also after including the antibody-positive individuals into the analysis.Conclusions This exploratory study finds an association of overweight/obesity with signs of pneumonia in COVID-19. This finding suggests that a signal proportional to body fat mass, such as the hormone leptin, impairs the body’s ability to clear SARS-CoV-2 before pneumonia develops. This hypothesis concurs with previous work and should be investigated further to possibly reduce the proportion of severe cases of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by LMU Klinikum, Helmholtz Zentrum Munchen, and the German Center for Diabetes Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ethics board, LMU medical faculty, Munich, GermanyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the Life&Covid study are available from the corresponding author upon reasonable request and within the frameworks of European data protection laws. ER -